J. H. M. Schellens

653 total citations
18 papers, 506 citations indexed

About

J. H. M. Schellens is a scholar working on Oncology, Molecular Biology and Organic Chemistry. According to data from OpenAlex, J. H. M. Schellens has authored 18 papers receiving a total of 506 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Molecular Biology and 3 papers in Organic Chemistry. Recurrent topics in J. H. M. Schellens's work include Cancer Treatment and Pharmacology (5 papers), Cancer therapeutics and mechanisms (4 papers) and Glioma Diagnosis and Treatment (2 papers). J. H. M. Schellens is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Cancer therapeutics and mechanisms (4 papers) and Glioma Diagnosis and Treatment (2 papers). J. H. M. Schellens collaborates with scholars based in Netherlands, United States and Italy. J. H. M. Schellens's co-authors include Jos H. Beijnen, Olaf van Tellingen, Manon Huizing, Vinodh R. Nannan Panday, W J Nooijen, Mirjam Crul, G.J.M. de Klerk, J. H. Beijnen, A. Bult and José Jimeno and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

J. H. M. Schellens

17 papers receiving 480 citations

Peers

Countries citing papers authored by J. H. M. Schellens

Since Specialization

Citations

This map shows the geographic impact of J. H. M. Schellens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. H. M. Schellens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. H. M. Schellens more than expected).

Fields of papers citing papers by J. H. M. Schellens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. H. M. Schellens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. H. M. Schellens. The network helps show where J. H. M. Schellens may publish in the future.

Co-authorship network of co-authors of J. H. M. Schellens

This figure shows the co-authorship network connecting the top 25 collaborators of J. H. M. Schellens. A scholar is included among the top collaborators of J. H. M. Schellens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. H. M. Schellens. J. H. M. Schellens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study 2017 ·Annals of Oncology ·Janice M. Mehnert, Hope S. Rugo, Bert H. O’Neil, Armando Santoro, J. H. M. Schellens, Rachel Cohen, Toshihiko Doi, (unknown), Michael J. Pishvaian, Igor Puzanov, Kyaw Aung, Chih‐Hung Hsu, Christophe Le Tourneau, J.C. Soria, Élena Elez, (unknown), (unknown), Guojun Zhao, Karen Stein, Sarina A. Piha‐Paul	42
2	Phase I dose escalation and expansion study to evaluate safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors 2015 ·Annals of Oncology ·Brigette Ma, Yung‐Jue Bang, Wan‐Teck Lim, Do‐Hyun Nam, (unknown), J. H. M. Schellens, (unknown), Mikhail Akimov, (unknown), Arun Kumar, (unknown), Martin Schüler	4
3	Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028 2015 ·Cancer Research ·Evan Alley, L Rhoda Molife, Armando Santoro, (unknown), Sammy Yuan, Jonathan D. Cheng, Bilal Piperdi, J. H. M. Schellens	29
4	Selection of oncology medicines in low- and middle-income countries 2013 ·Annals of Oncology ·(unknown), A. de Boer, J. H. M. Schellens, H.G.M. Leufkens, Aukje K. Mantel‐Teeuwisse	27
5	Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor. 2011 ·Journal of Clinical Oncology ·Suzanne Leijen, Mark R. Middleton, Patricia Tresca, Françoise Kraeber‐Bodéré, Véronique Dièras, M. E. Scheulen, Jean Tessier, Zhixin Xu, Eliezer Shochat, Antje‐Christine Walz, Jonathan Deutsch, (unknown), (unknown), (unknown), J. H. M. Schellens, Wilfried Eberhardt	7
6	Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. 2011 ·Journal of Clinical Oncology ·J. H. M. Schellens, Geoffrey I. Shapiro, Anne C. Pavlick, Raoul Tibes, Suzanne Leijen, SM Tolaney, Iván Díaz-Padilla, Ramesh K. Ramanathan, Tim Demuth, (unknown), J. Cheng, Raymond W. Lam, Yingru Xu, Amit M. Oza	14
7	Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers 2006 ·European Journal of Clinical Pharmacology ·Markus Joerger, Tessa M. Bosch, Valerie D. Doodeman, J. H. Beijnen, Paul H.M. Smits, J. H. M. Schellens	23
8	Phase I study of combined treatment with the oral alkyl-lysophospholipid (ALP) Perifosine and radiation in patients with advanced solid tumors 2004 ·Journal of Clinical Oncology ·Marcel Verheij, Stefan R. Vink, J. H. M. Schellens, J. H. Beijnen, H. Sindermann, J. Engel, R. Dubbelman, (unknown), M. J. X. Hillebrand, H. Bartelink	2
9	Phase I and pharmacologic study of enzastaurin HCl, gemcitabine and cisplatin 2004 ·Journal of Clinical Oncology ·Jeany M. Rademaker-Lakhai, (unknown), Els O. Witteveen, Sandra A. Radema, Carla Visseren‐Grul, Luna Musib, (unknown), J. H. Beijnen, J. H. M. Schellens, (unknown)	2
10	Phase I and pharmacological study of oral topotecan and the BCRP and P-gp inhibitor elacridar 2004 ·Journal of Clinical Oncology ·J. H. M. Schellens, I. E. L. M. Kuppens, Roxanne C. Jewell, Sandra A. Radema, Els O. Witteveen, Elaine Paul, (unknown), Hilde Rosing, (unknown), (unknown)	1
11	Ras biochemistry and farnesyl transferase inhibitors: a literature survey 2001 ·Anti-Cancer Drugs ·Mirjam Crul, G.J.M. de Klerk, Jos H. Beijnen, J. H. M. Schellens	73
12	UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial 2001 ·European Journal of Cancer ·Alain Ravaud, Markus Borner, J. H. M. Schellens, L. Geoffrois, (unknown), (unknown), J. Wanders, A.-R. Hanauske, P. Fumoleau	23
13	Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9 2001 ·Anti-Cancer Drugs ·J. H. M. Schellens, P Dombernowsky, Jim Cassidy, Ron Epelbaum, Luc Dirix, Eugène Cox, J. Wanders, F. Calabresi, Robert Paridaens, S. Monfardini, Johannes Wolff, Walter J. Loos, Jaap Verweij, Nikolaos Pavlidis, (unknown)	11
14	Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer 2001 ·Anti-Cancer Drugs ·J. H. M. Schellens, A.S.T. Planting, Jun Ma, Marc Maliepaard, Alex de Vos, (unknown), Jaap Verweij	17
15	Pharmaceutical development of anticancer agents derived from marine sources 2000 ·Anti-Cancer Drugs ·Bastiaan Nuijen, Marjan Bouma, (unknown), José Jimeno, J. H. M. Schellens, A. Bult, J. H. Beijnen	52
16	Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma) 2000 ·Cancer Chemotherapy and Pharmacology ·C.M.F. Kruijtzer, (unknown), (unknown), J. H. M. Schellens	12
17	Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands 2000 ·Anti-Cancer Drugs ·(unknown), Jaap Verweij, J. H. M. Schellens, Jos H. Beijnen, L. Pronk, Mario Bo, Vera Lustig, Harm van Tinteren, Martin Mackay, W.W. ten Bokkel Huinink	8
18	Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients 1999 ·British Journal of Cancer ·Olaf van Tellingen, Manon Huizing, Vinodh R. Nannan Panday, J. H. M. Schellens, W J Nooijen, Jos H. Beijnen	159

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact